The FDA's Skin Facts! Initiative is aimed at promoting safe use of skin care products, urging people to be aware of non-prescription products marketed to lighten or bleach the skin.
Despite the growing popularity of “clean” beauty products, industry veterans say terms like “natural” and “organic” are unregulated and often meaningless. Here’s why that’s the case.The FDA has launched an initiative warning about over-the-counter skin lightening products after receiving reports of side effects., announced last week, is aimed at promoting safe use of skin care products, urging people to be aware of non-prescription products marketed to lighten or bleach the skin.
Doctors and other experts say people of color are most at risk, and may also be using these products to lighten their skin color, an issue rooted in colorism. “It's really an important part of our toolbox in treating these pigmentary conditions, which tend to occur in minority, skin-of-color patients,” she said.
To better understand use of skin-lightening products for hyperpigmentation, the most common skin complaint from people of color, the Reagan-Udall Foundation, a research group under the FDA, conducted listening sessions with Black, Asian and American Indian and Alaska Native communities, and consulted experts.Joanne Rondilla, a San Jose State University sociologist, expert on colorism and former cosmetic industry worker, was among them.
Her own experiences led her to research the issue. Growing up, she was darker than her sisters. Her mother forbade her from swimming so she wouldn’t get darker. Television often featured lighter-skinned actresses, and relatives made comments. In her research, she found these experiences in other women’s lives, too.
“When I would dive deeper and ask, ‘Well, what does this look like, descriptively?’ It would be, ‘lighter skin’ or 'clearer skin,'” she said.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA Approves Oral TYK2 Inhibitor for Treating PsoriasisDeucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first drug in this class to be approved.
Consulte Mais informação »
FDA warns of rare cases of cancers possibly linked to breast implantsWhile rare, the FDA is warning about certain cancers, including squamous cell carcinoma and various lymphomas, that may develop in scar tissue that forms around breast implants.
Consulte Mais informação »
Congress hits home stretch renewing FDA user fee programsThe FDA could begin sending furlough notices to staff if lawmakers don't settle on a mechanism for reviewing prescription drugs, medical devices, generic drugs and biosimilars.
Consulte Mais informação »
More Than 200 Cases of a Bottled Starbucks Drink Have Been RecalledThey may have been contaminated with metal fragments, the FDA said.
Consulte Mais informação »
FDA approves over-the-counter hearing aids to lower costs, increase accessEighty percent of people who would benefit from hearing aids don't wear them, according to the National Institutes of Health. That's because of cost, access and stigma. However, a new move by the FDA may change all of that.
Consulte Mais informação »